Literature DB >> 33540778

In Vitro Characterization of Twenty-One Antifungal Combinations against Echinocandin-Resistant and -Susceptible Candida glabrata.

Hazim O Khalifa1,2, Hidetaka Majima1, Akira Watanabe1, Katsuhiko Kamei1.   

Abstract

This study was designed to analyze the interaction of 21 antifungal combinations consisting of seven major antifungal agents against 11 echinocandin- susceptible and six-resistant C. glabrata isolates. The combinations were divided into five major groups and were evaluated by checkerboard, disc diffusion, and time-killing assays. Synergy based on the fractional inhibitory concentration index of ≤0.50 was observed in 17.65-29.41% of the cases for caspofungin combinations with azoles or amphotericin B. Amphotericin B combination with azoles induced synergistic interaction in a range of 11.76-29.41%. Azole combinations and 5-flucytosine combinations with azoles or amphotericin B did not show synergistic interactions. None of the 21 combinations showed antagonistic interactions. Interestingly, 90% of the detected synergism was among the echinocandin-resistant isolates. Disk diffusion assays showed that the inhibition zones produced by antifungal combinations were equal to or greater than those produced by single drugs. The time-killing assay showed the synergistic action of caspofungin combination with fluconazole, voriconazole, and posaconazole, and the amphotericin B-5-flucytosine combination. Furthermore, for the first time, this assay confirmed the fungicidal activity of caspofungin-voriconazole and amphotericin B-5-flucytosine combinations. The combination interactions ranged from synergism to indifference and, most importantly, no antagonism was reported and most of the synergistic action was among echinocandin-resistant isolates.

Entities:  

Keywords:  C. glabrata; FKS mutations; antifungal synergistic combinations; echinocandins; echinocandins resistance

Year:  2021        PMID: 33540778      PMCID: PMC7912999          DOI: 10.3390/jof7020108

Source DB:  PubMed          Journal:  J Fungi (Basel)        ISSN: 2309-608X


  33 in total

1.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

2.  Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

Authors:  A Louie; P Kaw; P Banerjee; W Liu; G Chen; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 3.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.

Authors:  A Louie; P Banerjee; G L Drusano; M Shayegani; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Genetic Basis of Azole and Echinocandin Resistance in Clinical Candida glabrata in Japan.

Authors:  Hazim O Khalifa; Teppei Arai; Hidetaka Majima; Akira Watanabe; Katsuhiko Kamei
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

7.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

8.  FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.

Authors:  Nicholas D Beyda; Julie John; Abdullah Kilic; Mohammad J Alam; Todd M Lasco; Kevin W Garey
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

9.  In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.

Authors:  D T A Te Dorsthorst; P E Verweij; J Meletiadis; M Bergervoet; N C Punt; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.

Authors:  Ana C Mesa-Arango; Liliana Scorzoni; Oscar Zaragoza
Journal:  Front Microbiol       Date:  2012-08-08       Impact factor: 5.640

View more
  4 in total

1.  Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection.

Authors:  Hazim O Khalifa; Vit Hubka; Akira Watanabe; Minoru Nagi; Yoshitsugu Miyazaki; Takashi Yaguchi; Katsuhiko Kamei
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

2.  Bioactive triterpenoids from Solanum torvum fruits with antifungal, resistance modulatory and anti-biofilm formation activities against fluconazole-resistant candida albicans strains.

Authors:  Benjamin Kingsley Harley; David Neglo; Philip Tawiah; Mercy Adansi Pipim; Nana Ama Mireku-Gyimah; Clement Okraku Tettey; Cedric Dzidzor Amengor; Theophilus Christian Fleischer; Sayanika Devi Waikhom
Journal:  PLoS One       Date:  2021-12-28       Impact factor: 3.240

Review 3.  Echinocandins - structure, mechanism of action and use in antifungal therapy.

Authors:  Mateusz Szymański; Sandra Chmielewska; Urszula Czyżewska; Marta Malinowska; Adam Tylicki
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

4.  Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative Against Candida albicans.

Authors:  Daniella Renata Faria; Raquel Cabral Melo; Glaucia Sayuri Arita; Karina Mayumi Sakita; Franciele Abigail Vilugron Rodrigues-Vendramini; Isis Regina Grenier Capoci; Tania Cristina Alexandrino Becker; Patrícia de Souza Bonfim-Mendonça; Maria Sueli Soares Felipe; Terezinha Inez Estivalet Svidzinski; Erika Seki Kioshima
Journal:  Pathogens       Date:  2021-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.